Selpercatinib and capmatinib combination promotes sustained complete response in novel ISOC1-RET fusion lung cancer after resistance to RET inhibitor via MET amplification: Case Report

RET fusions occur in 1–2% of non-small cell lung cancer. Selpercatinib and pralsetinib are selective RET inhibitors with significant improvement of outcome in patients with tumor harboring RET fusion; however, resistance mechanisms appear frequently, mainly driven by MAPK pathway bypass, secondary R...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Caio Abner Leite, Raíssa Pierri Carvalho, Felipe Marques da Costa, Augusto Kreling Medeiros, Fabio Augusto Schutz, William Nassib William
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2023-10-01
Serija:	Frontiers in Oncology
Teme:	lung adenocarcinoma RET fusion MET amplification selpercatinib capmatinib
Online dostop:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1264231/full
Oznake:	Označite Brez oznak, prvi označite!